A pharmacogenetic versus a clinical algorithm for warfarin dosing.
暂无分享,去创建一个
R. Califf | Jeffrey L. Anderson | N. Geller | Y. Rosenberg | J. Halperin | B. Gage | S. Kimmel | N. Limdi | M. Caldwell | S. Kasner | R. Madigan | S. Goldhaber | J. Ellenberg | Julie A. Johnson | C. Eby | E. Mohler | B. French | R. McBane | S. Z. Abdel‐Rahman | S. Stevens | S. Yale | M. Fang | Vinay Shah | R. Horenstein | J. Muldowney | J. Gujral | P. Delafontaine | R. Desnick | T. Ortel | H. Billett | R. Pendleton | Robert B McBane
[1] F R Rosendaal,et al. A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy , 1993, Thrombosis and Haemostasis.
[2] Vittorio Pengo,et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT) , 1996, The Lancet.
[3] B. Horne,et al. Randomized Trial of Genotype-Guided Versus Standard Warfarin Dosing in Patients Initiating Oral Anticoagulation , 2007, Circulation.
[4] G. Raskob,et al. Idraparinux versus standard therapy for venous thromboembolic disease. , 2007, The New England journal of medicine.
[5] M. Rieder,et al. A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. , 2008, Blood.
[6] Y. Caraco,et al. CYP2C9 Genotype‐guided Warfarin Prescribing Enhances the Efficacy and Safety of Anticoagulation: A Prospective Randomized Controlled Study , 2008, Clinical pharmacology and therapeutics.
[7] M. Rieder,et al. Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of Warfarin , 2008, Clinical pharmacology and therapeutics.
[8] C. Thorn,et al. Dosing Algorithms to Predict Warfarin Maintenance Dose in Caucasians and African Americans , 2008, Clinical pharmacology and therapeutics.
[9] Janet Woodcock,et al. Pharmacogenetics--tailoring treatment for the outliers. , 2009, The New England journal of medicine.
[10] R. Altman,et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. , 2009, The New England journal of medicine.
[11] S. Yusuf,et al. Dabigatran and Warfarin in Vitamin K Antagonist–Naive and –Experienced Cohorts With Atrial Fibrillation , 2010, Circulation.
[12] R L Berg,et al. Integration of Genetic, Clinical, and INR Data to Refine Warfarin Dosing , 2010, Clinical pharmacology and therapeutics.
[13] R. Verbrugge,et al. Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study). , 2010, Journal of the American College of Cardiology.
[14] Jeffrey L. Anderson,et al. Statistical design of personalized medicine interventions: The Clarification of Optimal Anticoagulation through Genetics (COAG) trial , 2010, Trials.
[15] N. Geller,et al. Prospective alpha allocation in the clarification of optimal anticoagulation through genetics (COAG) trial , 2010, Clinical trials.
[16] R. Investigators. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. , 2010, American heart journal.
[17] W. Burke,et al. Debating Clinical Utility , 2010, Public Health Genomics.
[18] Geoffrey S Ginsburg,et al. The long and winding road to warfarin pharmacogenetic testing. , 2010, Journal of the American College of Cardiology.
[19] Richard L Berg,et al. A randomized controlled trial of genotype-based Coumadin initiation , 2011, Genetics in Medicine.
[20] E. Ashley,et al. Genetics and Cardiovascular Disease: A Policy Statement From the American Heart Association , 2012, Circulation.
[21] Xilong Lang,et al. Clinical Application of Pharmacogenetic-Based Warfarin-Dosing Algorithm in Patients of Han Nationality after Rheumatic Valve Replacement: A Randomized and Controlled Trial , 2012, International journal of medical sciences.
[22] Jeffrey L. Anderson,et al. Genetics InFormatics Trial (GIFT) of Warfarin to Prevent Deep Vein Thrombosis (DVT): Rationale and Study Design , 2011, The Pharmacogenomics Journal.
[23] L. Cavallari,et al. The future of warfarin pharmacogenetics in under-represented minority groups. , 2012, Future cardiology.
[24] Munir Pirmohamed,et al. Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy , 2011, Thrombosis and Haemostasis.
[25] B. Horne,et al. A Randomized and Clinical Effectiveness Trial Comparing Two Pharmacogenetic Algorithms and Standard Care for Individualizing Warfarin Dosing (CoumaGen-II) , 2012, Circulation.
[26] R. Califf,et al. Rationale and design of the Clarification of Optimal Anticoagulation through Genetics trial. , 2013, American heart journal.
[27] D. Xavier,et al. Apixaban versus Warfarin in Patients with Atrial Fibrillation , 2012 .